Poveda, Andres
Oaknin, Ana
Romero, Ignacio
Guerrero-Zotano, Angel
Fariñas-Madrid, Lorena
Rodriguez-Freixinos, Victor
Mallol, Pedro
Lopez-Reig, Raquel
Lopez-Guerrero, Jose Antonio
Funding for this research was provided by:
PharmaMar
AstraZeneca Spain
Article History
Received: 1 October 2020
Accepted: 22 January 2021
First Online: 24 February 2021
Competing interests
: AP declared consulting/advisory role for AstraZeneca, PharmaMar, Roche, Clovis Oncology, Tesaro, support for travel and accommodations from PharmaMar. AO has served on advisory boards for Roche, AstraZeneca, PharmaMar, Clovis Oncology, Tesaro, Immunogen and Genmab and received support for travel or accommodation from Roche, AstraZeneca, and PharmaMar; and received research funding paid directly to her Institution from Abbvie Deutschland, Abililty Pharmaceuticals, Advaxis Inc., Aeterna Zentaris, AMGEM, SA, Aprea Therapeutics AB, Clovis Oncology Inc, EISAI limited LTD, F. Hoffmann—La Roche LTD, Regeneron Pharmaceuticals, Immunogen Inc., Merck, Sharp & Dohme de España SA, Millennium Pharmaceuticals Inc., PharmaMar SA, Tesaro Inc., BMS. IR declared personal honoraria from Roche, PharmaMar, Tesaro, AstraZeneca, Clovis. AG declared personal honoraria from Roche, AstraZeneca, Novartis, MSD, Pfizer, advisory/consulting role for AstraZeneca, Novartis, MSD, Pierre-Fabre, Travel, Accommodation and Expenses paid by Roche, Novartis, Pfizer, research funding (to institution) from Pfizer. LF declared advisory/consultancy role for TESARO, GSK, speaks fees from AstraZeneca, Roche, MSD. VR had none to declare. PM declared no competing interests. RL declared no competing interests. JAL declared advisory/consultancy role for AstraZeneca, MSD, speaker fees from AstraZeneca, Sophia Genetics, research funding (to institution) from Generalitat Valenciana, Instituto de Salud Carlos III; PharmaMar, AstraZeneca.